sclerosis drug Drugmaker – Drugmaker Lupine on Friday said it has received approval from the US health regulator to market a generic drug to treat multiple sclerosis. The company has received provisional approval from the US Food and Drug Administration (USFDA) for an abbreviated new drug application for siponimod tablets in the strengths of 0. 25 mg, 1 mg and 2 mg, the Mumbai-based drugmaker said in a statement.

The new product will be manufactured at the company’s manufacturing facility in Pithampur. Siponimod tablets, 0.

25 mg, 1 mg and 2 mg, are bioequivalent to Novartis Pharmaceuticals Corporation’s Mayzent tablets, and are indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease in adults. According to IQVIA MAT October 2025 data, siponimod tablets had projected annual sales of US$195 million in the US. Lupine shares were trading 0.

42 per cent higher at Rs 2,100. 80 on the BSE.